Results 51 to 60 of about 261 (136)

EHA2021 Virtual Congress Abstract Book

, 2021
HemaSphere, Volume 5, Issue S2, June 2021.
wiley   +1 more source

DFFR: A New Method for High-Throughput Recalibration of Automatic Force-Fields for Drugs [PDF]

, 2020
We present drug force-field recalibration (DFFR), a new method for refining of automatic force-fields used to represent small drugs in docking and molecular dynamics simulations.
Juan Aranda, Soliva, Robert, Orozco López, Modesto, Moreno Fajardo, David Fernando, Hospital Gasch, Adam, Adam Hospital, David Moreno, Modesto Orozco, Francesco Colizzi, Colizzi, Francesco, Sanja Zivanovic, Zivanovic, Sanja, Aranda, Juan, Robert Soliva   +13 more
core   +1 more source

Transformer‐based representation learning and multiple‐instance learning for cancer diagnosis exclusively from raw sequencing fragments of bisulfite‐treated plasma cell‐free DNA

Molecular Oncology, Volume 18, Issue 11, Page 2755-2769, November 2024.
This study introduces DECIDIA, a deep‐learning approach for early cancer diagnosis using bisulfite‐treated cfDNA sequencing fragments. Utilizing transformer‐based representation learning and weakly supervised multiple‐instance learning, DECIDIA accurately detects cancer and predicts cancer types, significantly simplifying data analysis.
Jilei Liu, Hongru Shen, Yichen Yang, Meng Yang, Qiang Zhang, Kexin Chen, Xiangchun Li   +6 more
wiley   +1 more source

Plasma Cell‐Free DNA Concentration and Fragmentomes Predict Neoadjuvant Chemotherapy Response in Cervical Cancer Patients

Advanced Science, Volume 11, Issue 43, November 20, 2024.
Cervical cancer patients with varying responses to neoadjuvant chemotherapy (NACT) exhibit unique patterns of variation in cell‐free DNA (cfDNA) levels and fragmentomic characteristics. The cfDNA emerges as a promising biomarker for predicting tumor response to NACT in cervical cancer, offering a novel approach for monitoring treatment response to ...
Ting Peng, Haiqiang Zhang, Lingguo Li, Canhui Cao, Miaochun Xu, Xiaojie Liu, Shitong Lin, Ping Wu, Tian Chu, Binghan Liu, Yashi Xu, Yan Zhang, Yeqin Wang, Jinjin Yu, Wencheng Ding, Xin Jin, Peng Wu   +16 more
wiley   +1 more source

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges

MedComm, Volume 5, Issue 11, November 2024.
The origin of ctDNA in the bloodstream is derived from CTC, exosomes secreted by tumor cells, apoptotic tumor cells and necrotic tumor cells (A). ctDNA methylation status plays an important role in the occurrence and development of cancer and is a biomarker for tumor liquid biopsy.
Lingyu Li, Yingli Sun
wiley   +1 more source

Advances in early detection of non‐small cell lung cancer: A comprehensive review

Cancer Medicine, Volume 13, Issue 18, September 2024.
Abstract Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and ...
Nour Kenaan, George Hanna, Moustafa Sardini, Mhd Omar Iyoun, Khedr Layka, Zein Alabdin Hannouneh, Zuheir Alshehabi   +6 more
wiley   +1 more source

Circulating Cell-free DNA Fragmentomics Detection and Beyond

aging and disease
Circulating cell-free DNA (cfDNA) comprises DNA fragments released into bodily fluids via apoptosis, necrosis, or phagocytosis. cfDNA encapsulates both fragmentomics (structural) and non-fragmentomics (sequence/epigenetic) information from source cells, thereby representing a promising biomarker.
Tianliang, Liu, Zhicheng, Li, Shifu, Chen, Jiasheng, Zhong   +3 more
openaire   +2 more sources

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer, Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese, Amy Taylor, Katie R. Kaufmann, Hannah Krause, Jennifer Schehr, Nan Sethakorn, David Kosoff, Christos E. Kyriakopoulos, Michael Bassetti, Grace Blitzer, John Floberg, Martin Sjöström, Andrew J. Armstrong, Himisha Beltran, Rana R. McKay, Felix Y. Feng, Ruth O’Regan, Kari B. Wisinski, Hamid Emamekhoo, Alex W. Wyatt, Joshua M. Lang, Shuang G. Zhao   +26 more
openaire   +3 more sources

Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]

Clinical Chemistry, 2020
Rossa W K Chiu, Ellen Heitzer, Y M Dennis Lo, Florent Mouliere, Dana W Y Tsui   +4 more
openaire   +1 more source

Long circulating-free DNA fragments predict early-progression (EP) and progression-free-survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): a new biomarker

International audienceBackgroundEstablishing reliable and early predictive biomarkers of response of ICI is essential. Analysis of cfDNA fragmentation profiles (fragmentome) is a promising non-invasive method to do so independently of a specific ...
Boutonnet, Audrey, Fina, Frederic, Nguyen Phuong, Linh, Tomasini, Pascale, Greillier, Laurent, Salas, Sébastien, Ginot, Frédéric, Deville, Jean-Laurent, Benzekry, Sébastien   +8 more
core   +2 more sources